Drug updated on 3/28/2024
| Dosage Form | Tablet (oral; 225 mg) |
| Drug Class | Kinase inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- For the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.
Summary
- Tepotinib (Tepmetko) is a therapeutic agent used for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.
- According to the systematic reviews and meta-analyses, Tepotinib has shown higher efficacy outcomes in treating NSCLC compared to chemotherapy or immunotherapy regimens, particularly among patients with METex14 skipping mutations.
- The median objective response rate ranged from 50.7% to 68.8% when using targeted therapies like Tepotinib as first line of treatment for NSCLC patients with METex14 skipping alterations.
- A total of three Systematic Reviews / Meta-Analyses were reviewed which indicated that elderly patients and those having adenocarcinoma histology are more likely to have METex14 skipping NSCLC, thus making them suitable candidates for MET inhibitor therapy such as Tepotinib.
- In terms of safety profile, adverse events reported during the use of Tepmetko were mild in most cases; common adverse events above grade 3 included lower extremity edema, alanine aminotransferase elevation and lipase elevation according to one meta-analysis study conducted.
- Treatment involving combination therapies including tepotinib may be potential solutions for overcoming resistance against other treatments such as epidermal growth factor receptor inhibitors based on findings from various clinical trials mentioned across all documents reviewed.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Tepmetko (tepotinib) Prescribing Information. | 2023 | EMD Serono, Inc. Rockland, MA |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Clinical, pharmacoeconomic, and stakeholder input combined report. | 2023 | CADTH |
| MET exon 14 skipping in NSCLC: a systematic literature review of epidemiology, clinical characteristics, and outcomes. | 2023 | Clinical Lung Cancer |
| Australian public assessment report for Tepmetko. | 2022 | Australian Government: Department of Health |
| Assessment report: Tepmetko. | 2022 | EMA |
| Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations | 2022 | NICE |
| MET-targeted therapies for the treatment of non-small-cell lung cancer: A systematic review and meta-analysis. | 2022 | Frontiers in Oncology |
| MET-targeted therapies and clinical outcomes: a systematic literature review. | 2022 | Molecular Diagnosis & Therapy |